About our DMPK Webinar on Low Clearance Compounds

Explore the latest in vitro strategies to support decision-making for low clearance compounds in drug discovery.

Join a panel of seasoned scientists and industry experts as we examine the complexities of low intrinsic clearance and how to address them through modern low clearance assays, in vitro models, and predictive data. This free session includes a concise scientific presentation followed by an interactive panel discussion covering validated methods, case studies, and novel insights from real-world drug development programs.

Register to watch our webinar on-demand

You can ask your own questions of our experts.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State

Email(Required)

Thank you for registering to watch our on-demand webinar. By submitting this form, you consent to the collection and processing of your personal data by Pharmaron in accordance with our Privacy Policy. You may be contacted by email following your webinar viewing regarding any questions you may have, as well as relevant services and updates. You can unsubscribe or withdraw your consent at any time.

What You’ll Learn

Attendees will gain a deeper understanding of:

Optimized in vitro low clearance assay methodologies
Emerging technologies for low turnover compound analysis
Strategic use of calibrated assay models in early drug discovery
Practical examples and case studies that inform data-driven decision-making

Why This Matters

Low clearance compounds present analytical challenges in early drug development. Without accurate in vitro modeling, researchers risk late-stage surprises or ineffective candidate progression. This webinar highlights the latest science and best practices for solving these challenges—and delivers actionable guidance from global leaders in the field.

Meet our Speakers

Moderated by:

Chris Bode – VP of Scientific Affairs at Pharmaron

As VP of Scientific Affairs, one of Dr. Bode’s responsibilities is to capture and disseminate the mission and messages of the company to the world. He has had multiple roles since joining the company known as Absorption Systems at the time, in 2006. He is Study Director for most of the Biopharmaceutics Classification System (BCS) studies conducted in support of numerous BCS-based biowaivers. He has also directed studies focused on transporters, CYP induction, inhibition, and phenotyping, serves as Scientific Reviewer for many other studies, and either directs or provides scientific input into various research projects, grants, and contracts. Previously, Dr. Bode spent seventeen years in the pharmaceutical industry, working on both pharmacokinetics and pharmacodynamics. His Ph.D. in pharmacology is from the University of Colorado, and postdoctoral research was conducted at UC San Diego.

Speakers:

Carl Petersson – Scientific Director at Merck Healthcare KGaA

Carl Petersson works at Merck Healthcare KGaA in Darmstadt, Germany, as a scientific director, NCE DMPK. In this position, he is offering strategic, educational, and hands-on support to optimize and predict ADME properties of small molecules. In addition, he is serving on several multidisciplinary drug discovery teams, in which he is responsible for the pharmacokinetic and drug metabolism contributions. Before joining his current company, he worked 12 years at the CNS & Pain unit of AstraZeneca in roles such as Associate Director Biotransformation and Associate director Discovery DMPK. Dr. Petersson more than 40 scientific publications in peer review journals and has a Ph.D. in Organic chemistry obtained at the Swedish University of Agricultural sciences. He did his postdoctoral research at the University of Alberta, Edmonton, Canada.

**Katherine Fenner – in vitro DMPK Laboratory Head at Pharmaron**

Katherine Fenner is responsible for Pharmaron’s in vitro DMPK provision in UK & Europe. Katherine has over 30 years of experience in DMPK, working previously in several roles across both discovery and development DMPK for Pfizer and then AstraZeneca, where she directed an international in vitro ADME (absorption, distribution, metabolism & excretion) group. Katherine has published many peer-reviewed publications, including several on drug-drug interactions, recently publishing a Pharm IQ paper, focused on in vitro transporter assessment and implications for Drug Development.